NCT02046759

Brief Summary

The aim of the study is to compare the effect of asthma care by clinical pharmacist intervention versus routine care on asthma control.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2012

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2013

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

January 24, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 28, 2014

Completed
Last Updated

January 28, 2014

Status Verified

January 1, 2014

Enrollment Period

10 months

First QC Date

January 24, 2014

Last Update Submit

January 24, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Asthma Control Questionnaire

    at baseline & after 2 months of therapy

Secondary Outcomes (5)

  • Forced Expiratory Volume in 1 second (FEV1%)

    at baseline & after 2 months of therapy

  • Rescue Medication SABA (number of puffs used most days)

    at baseline & after 2 months of therapy

  • Inhaled Corticosteroid Use (number of puffs used/day)

    at baseline & after 2 months of therapy

  • Number of courses of systemic steroid used

    During 2 months of therapy

  • Number of ER visits/ Hospitalization

    During 2 months of therapy

Other Outcomes (2)

  • Assessment of Inhalation Technique

    at baseline and after 2 months of therapy

  • Patient Adherence to Therapy

    2 months of therapy

Study Arms (2)

Pharmacist-Intervention

EXPERIMENTAL
Other: Pharmacist- Intervention

Routine Care

ACTIVE COMPARATOR
Other: Routine Care

Interventions

Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.

Also known as: Patient Education, Asthma Action Plan, Shared Decision Making
Pharmacist-Intervention

Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.

Routine Care

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient with clinical diagnosis of bronchial asthma
  • responsible for administering their own asthma medications.

You may not qualify if:

  • patients who were not responsible for administering their own asthma medications.
  • patients with cognitive defects, other pulmonary disease e.g. Chronic Obstructive Pulmonary Disease (COPD), experiencing illness with asthma-like symptoms e.g. Congestive Heart Failure, evidence of fixed airway obstruction
  • patients unavailable for 2-month follow-up.
  • patients who did not provide written informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams University Hospitals

Cairo, Egypt

Location

MeSH Terms

Conditions

Asthma

Interventions

Patient Education as Topic

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

Health EducationPreventive Health ServicesHealth ServicesHealth Care Facilities Workforce and Services

Study Officials

  • Rana R Farrag

    Ahram Canadian University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Pharmacist

Study Record Dates

First Submitted

January 24, 2014

First Posted

January 28, 2014

Study Start

March 1, 2012

Primary Completion

January 1, 2013

Study Completion

January 1, 2013

Last Updated

January 28, 2014

Record last verified: 2014-01

Locations